Thalassaemic bone disease: An overview

Pediatric Endocrinology Reviews

Volumn 6, Issue SUPPL. 1, 2008, Pages 73-80

  Angastiniotis, Michael ^a   Eleftheriou, Androulla ^a  

^a Thalassaemia International Federation   (Cyprus)

Author keywords

Bone disease; Bone marrow expansion; Endocrine complications; Osteoporosis; Thalassaemia

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DEFERIPRONE; DEFEROXAMINE; GLUCOCORTICOID; IRON; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ARTHROPATHY; BLOOD TRANSFUSION; BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE LESION; BONE MARROW; BONE NECROSIS; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; IRON CHELATION; IRON OVERLOAD; JAW DISEASE; MONITORING; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; SMOKING; THALASSEMIA;

BONE DISEASES; HUMANS; THALASSEMIA;

EID: 58149490843     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Cooley TB, Lee P. Series of cases of Splenomegaly in children with anaemia and peculiar bone changes. Trans Am Pediatr Soc 1925;37:29
2. Cooley TB, Witwer ER, Lee P. Anaemia in children with splenomegaly and peculiar changes in the bone. Am J. Dis Child 1927;34:347-363
3. Johnstone FE, Roseman JM. The effects of more frequent blood transfusions upon bone loss in thalassaemia major. Pediatr Res 1967;1:479-483
4. Piomelli S, Danoff SJ, Becker MH, Lipera MJ, Travis SF. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early huypertransfusion regimen. Ann N Y Acad Sci 1969;165:427-436
5. Finch CA, Deubelbeiss K, Cook JD, Eschbach JW, Harker LA, Funk DD, Marsaglia G, Hillman RS, Slichter S, Adamson JW, Ganzoni A, Biblett ER. Ferrokinetics in man. Medicine (Baltimore) 1970;49:17-53
6. Weinberg ED. Iron loading: a risk factor for osteoporosis. Biometals 2006;19:633-635
7. De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podds G, Fodde M, Pirastu GF, Cao A. Deferoxamine - induced growth retardation in patients with thalassemia major. J Pediatr 1988;113:661-669
8. Rioja L, Girot R, Garabedian M, Cournot - Witmer G. Bone disease in children with homozygous beta-thalassemia. Bone Miner 1990;8:69-86
9. Levin TL, Sheth SS, Ruzat-Shapiro C, Abramson S, Piomelli S, Berdon WE. MRI marrow observations in thalassemia: the effects of the primary disease, transfusional therapy, and chelation. Pediatr Radiol 1995;25:607-613
10. Angastiniotis M, Pavlides N, Aristidou K, Kanakas A, Yerakaris M, Eracleous E, Posporis T. Bone pain in thalassaemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3):779-784
11. De Vernejoul MC, Girot R, Gueris J, Cancela L, Bang S, Bielakoff J, Mautalen C, Goldberg D, Miravet L. Calcium phosphate metabolism and boen disease in patients with homozygous thalassaemia. J Clin Endocrinol Meab 1982;54:276-281
12. Bordat C, Constans A, Bouet O, Blanc I, Truben CL, Girot R, Cournot G. Iron distribution in thalassaemia bone by energy-loss spectroscopy and electron spectroscopic imaging. Calcif Tissue Int 1993;53:29-37
13. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnscombat P, Choubtum L, Sriphrapradang A, Bomrongkitchaiporn S, Sirisriro R, Rajatanavin R. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 2003;88:3966-3972
14. Liu G, Men P, Kenner GH, Miller SC. Therapeutic effects of an oral chelator targeting skeletal tissue damage in experimental postmenopausal osteoporosis in rats. Hemoglobin 2008;32:181-190
15. Kudo H, Suzuki S, Watanabe A, Kikuchi H, Sassa S, Sakamoto S. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. Toxicology 2008;246:143-147
16. Sinigaglia L, Fargion S, Fracanzani AL, Binelli L, Battaferano N, Varenna M, Piperno A, Fiorelli G. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 1997;24:1809-1813
17. Guggenbuhl P, Deugnier Y, Boisdet JF, Rolland Y, Perdriger A, Pawlotsky Y, Chales G. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005;16:1809-1814
18. Brill PW, Winchester P, Giardina PJ, Cunningham Rundles S. Deferoxamine - induced bone dysplasia in patients with thalassemia major. AJR Am J Roentgenol 1991;156:561-565
19. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996;155:368-372
20. Miller TT, Caldwell G, Kaye JJ, Arkin S, Burke S, Brill PW. MR imaging of deferoxamine - induced bone dysplasia in an 8 year old female with thalassaemia major. Pediatr Radiol 1993;23:523-524
21. Chan Y, Li C, Chu WC, Pang L, Cheng JC, Chik KW. Deferoxamine-induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR imaging appearance. AJR Am J Roentgenol 2000;175:1561-1566
22. Tyler PA, Madani G, Chaudhuri R, Wilson LF, Dick EA. The radiological appearances of thalassaemia. Clin Radiol 2006;61:40-52
23. De Sanctis V, Savarino L, Stea S, Cervellati M, Ciapetti G, Tassinari L, Pizzoferrato A. Microstructural analysis of severe bone lesions in seven thalassaemic patients treated with deferoxamine. Calcif Tissue Int 2000;67:128-133
24. Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone disease in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxaine - induced bone dysplasia. Pediatr Radiol 2002;32:492-497
25. De Sanctis V, Stea S, Savarino L, Granchi D, Visentin M, Sprocati M, Govoni R, Pizzoferrato A. Osteochondrodystrophic lesions in chelated thalassemic patients: an histological analysis. Calcif Tissue Int 2000;67:134-140
26. Guo M, Song LP, Jiang Y, Liu W, Yu Y, Chen GQ. Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-lalpha independent mechanisms. Apoptosis 2006;11:67-77
27. Kim BM, Choi JY, Kim YJ, Woo HD, Chung HW. Desferrioxamine (DFX) has genotoxic effects on cultured human lymphocytes and induces the p53-mediated damage response. Toxicology 2007;18:229:226-235
28. Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, Olivieri NF. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994;343:1471-1472
29. Hoffbrand AV, Wonke B. Iron chelation therapy. J Intern Med 1997;740:37-41
30. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Pfa A, Schettini F, Stefano I, Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3 year study in Italian patients. Br J Haematol 2002;118:330-336
31. Kellenberger CJ, Schmugge M, Saurenmann T, Di Gennaro L, Eber SW, Willi UV, Babyn PS. Radiographic and MRI features of deferiprone-related arthropathy of the knee in patients with beta-thalassemia. AJR Am J Roentgenol 2004;183:989-994
32. Bisbocci D, Livorno P, Modina P, Gambino M, Damianbo P, Cantoni R, Villata E, Chiandussi L. Osteodystrophy in thalassemia major. Ann Ital Med Int 1993;8:224-226
33. Dresner Pollack R, Rachmilewitz E, Blumanfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000;11:902-907
34. Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D'Angelo E, Mirra N, Cannetti V, Zanaboni L, Tampieri B, Cappellini MD, Cavagnini F. Bone demineralization in adult thalassaemic patients: contribution of growth hormone and insulin-like growth factor I at different skeletal sites. Clin Edocrinol (Oxf) 2008;69:202-207
35. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Edocrinol (Oxf) 1995;42:279-287
36. Brandle M, Galeazzi RL, Morant R, Oesterle M. Osteopenia in beta-thalassemia major. Schweiz Med Wochenschr 1996;126:1867-1874
37. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998;103:911-915
38. Origa R, Fiumana E, Gamberini MR, Armari S, Mottes M, Sangalli A, Paglietti E, Galanello R, Borgna-Pirnatti C. Osteoporosis in beta-thalassemia: Clinical and genetic aspects. Ann N Y Acad Sci 2005;1054:451-456
39. Bielinski BK, Darbyshire PJ, Mathers L, Crabtree NJ, Kirk JM, Stirling HF, Shaw NJ. Impact of disordered puberty on bone density in beta-thalassemia major. Br J Haematol 2003;120:353-358
40. Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, Katounda E, Kaltsas D, Tollis G. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Bone Miner Metab 2006;24:138-145
41. Perrons L, Perrotta S, Raimondo P, Mucerino J, De Rosa C, Siciliani MC, Santoro N, Miraglia del Giudice E. Inappropriate leptin secretion in thalassaemia: a potential cofactor of pubertal timing derangement. J Pediatr Endocrinol Metab 2003;16:877-881
42. Karachaliou F, Vlachopapadopoulou E, Theochari M, Konstandellou E, Michalados S. Leptin levels in patients with thalassemia major. Minerva Pediatr 2006;58:373-378
43. Cirmanova V, Bayer M, Starka L, Zajickova K. The effect of leptin on bone - an evolving concept of action. Physiol Res 2008;57(Suppl.1):S143-S151
44. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, Erten S, Tuck S, Agnew JE, Raja K, Davies K, Hoffbrand AV. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11(Suppl 3):795-801
45. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, Gasparini P, Siciliani MC, Iolascon A. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000;111:461-466
46. Arisal O, Deviren A, Fenerci EY, Hacihanefioglu S, Ulutin T, Erkmen S, Buyru N. Polymorphism analysis in the COLIA1 gene of patients with thalassaemia major and intermedia. Haematotogia (Budap) 2002;32:475-482
47. Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassaemia major or intermedia. Bone 2006;38:888-892
48. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Shamshirsaz AA, Aghakhani S, Homayoun H, Larijani B. Metabolic and endocrinologic complications in beta-thalassemia major: a multicentre study in Tehran. BMC Endocr Disord 2003;3:4
49. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-448
50. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D. Bone resorption is increased in young adults with thalassemia major. Br J Haematol 2001;112:36-41
51. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, Franchina F, Maisano D, La Rosa M, Plota M, Crifò A, Meo A, Frisina N. The "lively" cytokines network in beta-Thalassaemia Major-related osteoporosis. Bone 2007;40:1588-1594
52. Di Stefano M, Chiabotto P, Roggia C, Garofalo F, Lala R, Piga A, Isaia GC. Bone mass and metabolism in thalassaemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab 2004;22:53-57
53. Vogiatzi MG, Autio KA, Schneider R, Giardina PJ. Low bone mass in prepubertral children with Thalassaemia major: insights into the pathogenesis of low bone mass in Thatassaemia. J Pediatr Endocrinol Metab 2004;17:1415-1421
54. Yazigi A, Malouf G, Inati-Khoriati A, Tamin H, Saab C. Bone mineral density in beta-thalassemic Lebanese children. J Musculoskelet Neuronal Interact 2002;2:463-468
55. Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ. Prevalence of fractures among Thalassemia syndromes in North America. Bone 2006;38:571-575
56. Ruggiero L, De Sanctis V. Multicentre study on prevelance of fractures in transfusion-dependent thalassaemic patients. J Pediatr Endocrinol Metab 1998;11(Suppl 3):773-778
57. Finsterbush A, Farber I, Mogle P, Goldfarb A. Fracture patterns in Thalassaemia. Clin Orthop Relat Res 1985;192:132-136
58. Hall-Craggs MA, Porter J, Gatehouse PD, Bydder GM. Ultrashort echo time (UTE) MRI of the spine in Thalassaemia. Br J Radiol 2004;77:104-110
59. Desigan S, Hall-Craggs MA, Ho CP, Eliahoo J, Porter JB. Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs. Skeletal Radiol 2006;35:95-102
60. Aesopos A, Tsironi M, Polonifi K, Baltopoulos P, Vaiopoulos G. Intervertebral disc calcification in Thalassaemia intermedia. Eur J Haematol 2008;80:164-167
61. Karimi M, Jamalian N, Rasekhi A, Kashef S. Magnetic resonance imaging (MRI) findings of joints in young beta-thalassemia major patients: fluid surrounding the scaphoid bone: a novel finding, as the possible effect of secondary hemochromatosis. J Pediatr Hematol Oncol 2007;29:393-398
62. Bagni B, Palazzi G, Bangi I, Caporali C, Froehlich W, Casolo A, Caputo C, Rossi S, Garetti E, Pansini F, Corazzari T, De Sanctis V, Massolo F. pQCT (quantitative peripheral tomography) and data evaluation of phosphocalcic metabolism in Thalassaemic patients. J Pediatr Endocrinol Metab 1998;11(Suppl 3):791-794
63. Danesi L, Cherubini R, Ciceri L, Graziadei G, Cappellini MD, Cavagnini F, Ortolani S. Evaluation of spine and hip bone density by DXA and QCT in thalassemic patients. J Pediatr Endocrinol Metab 1998;11(Suppl 3):961-962
64. Akpek S, Canadan D, Arac M, Ilgit ET. Evaluation of osteoporosis in thalassaemia by quantitative computed tomography: is it reliable? Pediatr Hematol Oncol 2001;18:111-116
65. Ladis VA, Gandaifis N, Papadopoulos EC, Garvas GM, Papassotiriou I, Korres DS, Kattamis CA. Bone density study at the distal radius, using pQCT analysis, in Greek thalassemic patients. Pediatr Endocrinol Rev 2004;2(Suppl 2):307-309
66. Mylona M, Leotsinides M, Alexansrides T, Zoumbos N, Dimopoulos PA. Comparison of DXA, QCT and trabecular structure in beta-thalassaemia. Eur J Haematol 2005;74:430-437
67. Angelopoulos NG, Katounda E, Rombopoulos G, Goula A, Kaltzidou V, Kaltsas D, Ioannis P, Tolis G. Evaluation of bone mineral density of the lumbar spines in patients with beta-Thalassaemia major with dual-energy x-ray absorptiometry and quantitative computed tomography: a comparison study. J Pediatr Hematol Oncol 2006;28:73-78
68. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001;12:570-575
69. Carmina E, Di Fede G, Napoli N, Renda G, Vitale G, Lo Pinto C, Bruno D, Malizia R, Rini GB. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 2004;74:68-71
70. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N. Bisphosphonates in the treatment of Thalassaemia-induced osteoporosis. Osteoporos Int 2002;13:644-649
71. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99
72. Gaudio A, Morabito N, Xourafa A, Macrí 1, Meo A, Morgante S, Trifiletti A, Lasco A, Frisina N. Bisphosphonates in the treatment of Thalassaemia-associates osteoporosis. J Endocrinol Invest 2008;31:181-184
73. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003;123:730-737
74. Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT. Intravenous zolendronic acid treatment in thalasaemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 2006;85:605-609
75. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E. Zolendronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-centre, randomized, placebo-controlted trial. Haematologica 2006;91:1193-1202
76. Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M, Crawford BA. A randomized, bouble-blind, placebo-controlled trial of intravenous zolendronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 2006;79:138-144
77. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F. Effect of zolendronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 2007;86:23-30
78. Inoue Y, Shimojo N, Suzuki S, Arima T, Tomiita M, Minagawa M, Kohno Y. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol 2008;27:909-912
79. Thorton J, Ashcroft D, O'Neill T, Elliott R, Adams J, Roberts C, Rooney M, Symmons D. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol Assess 2008;12:1-208
80. Chabner BA. Late toxicities of drugs: Bisphosphonates. Oncologist 2005;10:301-303
81. Stroup J, Kane MP, Abu-baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 2008;65:532-539
82. Blake GM, Fogelman I. Strontium ranelate: a novel treatment for post menopausal osteoporosis: a review of safety and efficacy. Clin Interv Aging 2006;1:367-375
83. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007;9(Suppl 1):S7